The regulatory clearance allows the once daily therapy to be prescribed and sold in the US market for the treatment of the neurodegenerative condition.
Wednesday, October 21, 2026
Story
FDA Approves AbbVie Once Daily Pill Juvmo for Parkinson's
Business25 days ago
AbbVie has received US regulatory authorization for a new Parkinson's disease treatment targeting adult patients. The US Food and Drug Administration approved the drug, marketed as Juvmo and known as tavapadon, to be administered as a once daily pill.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.